Keros Therapeutics (NASDAQ:KROS) Major Shareholder Adar1 Capital Management, Llc Sells 5,389,264 Shares

Key Points

• Adar1 Capital Management sold over 5.3 million shares of Keros Therapeutics stock, totaling approximately $95.7 million, marking a significant divestment by a major shareholder.
• Keros Therapeutics' stock price decreased by 4.0%, closing at $14.49, with a market cap of about $588.58 million.
• The company's quarterly earnings showed a surprising improvement, with an EPS of ($0.76), beating estimates, although revenue was far below expectations at $0.02 million.

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of Keros Therapeutics stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Keros Therapeutics Trading Down 4.0%

KROS stock traded down $0.60 on Wednesday, hitting $14.49. 5,809,068 shares of the company's stock traded hands, compared to its average volume of 895,095. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37. The stock has a market cap of $588.58 million, a price-to-earnings ratio of 46.74, a P/E/G ratio of 2.05 and a beta of 0.97. The stock has a fifty day moving average of $15.27 and a 200-day moving average of $14.17.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.38. The business had revenue of $0.02 million during the quarter, compared to analysts' expectations of $3.83 million. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The firm's quarterly revenue was up 49002.7% compared to the same quarter last year. During the same period last year, the company posted ($1.25) earnings per share. On average, equities research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on KROS. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. HC Wainwright decreased their price objective on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $30.00.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Keros Therapeutics by 31.1% in the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company's stock valued at $26,151,000 after purchasing an additional 609,212 shares in the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Keros Therapeutics by 6,294.5% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company's stock worth $15,147,000 after acquiring an additional 1,463,215 shares during the period. Federated Hermes Inc. raised its stake in Keros Therapeutics by 882.3% during the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company's stock worth $12,474,000 after acquiring an additional 1,099,519 shares in the last quarter. Geode Capital Management LLC raised its stake in Keros Therapeutics by 2.9% during the second quarter. Geode Capital Management LLC now owns 829,297 shares of the company's stock worth $11,073,000 after acquiring an additional 23,112 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company's stock worth $7,547,000 after acquiring an additional 205,022 shares in the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.